SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes GMP Inspection at Lupin’s API manufacturing facility in Visakhapatnam

11 Mar 2023 Evaluate

The United States Food and Drug Administration (USFDA) has completed a Pre-Approval and GMP Inspection at Lupin’s API manufacturing facility located in Visakhapatnam (Vizag), India. The inspection was conducted from March 6, 2023 to March 10, 2023 and concluded with no observations. This accomplishment is a testament to the company’s commitment to upholding global quality standards across all its manufacturing sites, and to provide quality affordable healthcare for all. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×